Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

101. Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding

Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding Article Text Therapeutics Randomised controlled trial Addition of omeprazole to dual

Evidence-Based Medicine (Requires free registration)2011

102. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. 21406646 2011 03 16 2011 03 17 2016 10 17 1538-3598 305 11 2011 Mar 16 JAMA JAMA Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. 1097-105 10.1001/jama.2011.290 High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after (...) percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined. To evaluate the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI. Randomized, double-blind, active-control trial (Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety [GRAVITAS]) of 2214 patients with high on-treatment reactivity 12 to 24 hours after PCI with drug-eluting stents at 83 centers in North

JAMA2011

103. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 22088980 2011 11 23 2011 11 28 2016 11 25 1538-3598 306 20 2011 Nov 23 JAMA JAMA Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 2221-8 10.1001/jama.2011.1703 Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose (...) of the antiplatelet drug clopidogrel. To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes. ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011. Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers

JAMA2011

104. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. 21685437 2011 06 20 2011 11 08 2016 12 15 1756-1833 342 2011 Jun 17 BMJ (Clinical research ed.) BMJ Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO (...) . Randomised treatment with ticagrelor (n=2601) versus clopidogrel (2615). Primary composite end point of cardiovascular death, myocardial infarction, and stroke; their individual components; and PLATO defined major bleeding during one year. 2183 (41.9%) patients had coronary angiography during their initial hospital admission, 1065 (20.4%) had percutaneous coronary intervention, and 208 (4.0%) had coronary artery bypass surgery. Cumulatively, 3143 (60.3%) patients had been managed non-invasively

BMJ2011 Full Text: Link to full Text with Trip Pro

105. Clopidogrel Teva Pharma B.V.

Clopidogrel Teva Pharma B.V. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. EMA/439548/2011 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Clopidogrel Teva Pharma B.V. International non proprietary name (...) : clopidogrel Procedure No. EMEA/H/C/001226 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Medicinal product no longer authorisedTable of contents Page 1. Background information on the procedure 3 1.1. Submission of the dossier 3 Scientific Advice: 3 Licensing status: 4 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 5 2.1. Introduction 5 2.2. Quality aspects 6 2.2.1. Introduction 6 2.2.2. Active Substance 6 2.2.3

European Medicines Agency - EPARs2011

106. Plavix (clopidogrel bisulfate)

Plavix (clopidogrel bisulfate) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Plavix (clopidogrel bisulfate) 75 mg Tablets Company: sanofi-aventis U.S. LLC Application No.: 020839s051 Approval Date: 05/06/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2011

107. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial 20678878 2010 10 04 2010 10 28 2013 11 21 1097-6809 52 4 2010 Oct Journal of vascular surgery J. Vasc. Surg. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. 825-33, 833.e1-2 10.1016/j.jvs.2010.04.027 Dual antiplatelet therapy with clopidogrel plus (...) acetylsalicylic acid (ASA) is superior to ASA alone in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention. We sought to determine whether clopidogrel plus ASA conferred benefit on limb outcomes over ASA alone in patients undergoing below-knee bypass grafting. Patients undergoing unilateral, below-knee bypass graft for atherosclerotic peripheral arterial disease (PAD) were enrolled 2 to 4 days after surgery and were randomly assigned to clopidogrel 75 mg/day plus

EvidenceUpdates2010

108. Interaction of clopidogrel and omeprazole.

Interaction of clopidogrel and omeprazole. Interaction of clopidogrel and omeprazole. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21067412 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2010 Nov 11;363(20):1977. doi: 10.1056/NEJMc1012022. Interaction of clopidogrel and omeprazole. , . Comment on [N Engl J Med. 2010] PMID: 21067412 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full

NEJM2010

109. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial

Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial 20595658 2010 07 27 2010 08 17 2016 11 22 1524-4628 41 8 2010 Aug Stroke Stroke Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic (...) Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. 1679-83 10.1161/STROKEAHA.110.586727 Disabling stroke is costly and considered by some patients a fate worse than death. We aimed to determine whether clopidogrel reduces the rate and functional severity of stroke among high vascular risk patients, including patients with previous transient ischemic attack or ischemic stroke, who were enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization

EvidenceUpdates2010

110. Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction

Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction | Clinical Correlations Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction July 28, 2010 By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D. Faculty Peer Reviewed Recent publications have described a potential drug interaction between clopidogrel (Plavix (...) ®) and proton pump inhibitors (PPIs). Several retrospective studies have concluded that the use of PPIs can lower the effectiveness of clopidogrel and as a result, increase the possibility of cardiovascular events. Limited data from prospective trials have yet to show a clinical significance from this potential interaction. The Food and Drug Administration (FDA) released an early communication about the ongoing safety review of clopidogrel and omeprazole on January 26, 2009. Over the next 10 months, the FDA worked

Clinical Correlations2010

111. Duration of clopidogrel therapy with drug-eluting stents.

Duration of clopidogrel therapy with drug-eluting stents. Duration of clopidogrel therapy with drug-eluting stents. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 20666628 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2010 Jul 29;363(5):488; author reply 490. doi: 10.1056/NEJMc1005624. Duration of clopidogrel therapy with drug-eluting stents. . Comment on [N Engl J Med. 2010] PMID: 20666628 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0

NEJM2010

112. Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study

Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study 20620737 2010 07 12 2010 07 30 2014 11 20 1558-3597 56 3 2010 Jul 13 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo (...) in the ONSET/OFFSET study. 185-93 10.1016/j.jacc.2010.01.062 We prospectively assessed cardiac and pulmonary function in patients with stable coronary artery disease (CAD) treated with ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET (A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease) study

EvidenceUpdates2010

113. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention

Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention 20538118 2010 06 11 2010 07 06 2013 11 21 1879-1913 105 12 2010 Jun 15 The American journal of cardiology Am. J. Cardiol. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. 1705-9 10.1016/j.amjcard.2010.01.348 (...) Recent studies have suggested that proton pump inhibitors (PPIs) might reduce the inhibitory effect of clopidogrel on platelet aggregation, possibly through inhibition of the hepatic cytochrome P450 2C19 (CYP2C19) isoenzyme. The prevalence of CYP2C19 loss-of-function alleles is much greater among East Asians than among other populations. Thus, potential drug interactions might be more apparent. Therefore, we conducted a nationwide, population-based study using the Taiwan National Health Insurance

EvidenceUpdates2010

114. Adding clopidogrel to standard therapy for acute myocardial infarction.

Adding clopidogrel to standard therapy for acute myocardial infarction. BestBets: Adding clopidogrel to standard therapy for acute myocardial infarction. Adding clopidogrel to standard therapy for acute myocardial infarction. Report By: Kate Rotheray - Visiting Scholar Search checked by Giles Cattermole - Assistant Professor Institution: Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Date Submitted: 22nd October 2009 Date Completed: 23rd March 2010 Last Modified: 14th (...) April 2010 Status: Green (complete) Three Part Question In [patients with acute ST-elevation MI] is [clopidogrel plus aspirin better than aspirin alone] at [reducing morbidity and mortality]? Clinical Scenario A 60 year old man presents to the Emergency Department (ED) with chest pain. The ECG shows an ST elevation MI. You give him oxygen, nitrates, aspirin and morphine and also start thrombolysis. You wonder whether giving him clopidogrel as well would be beneficial. Search Strategy (OVID interface

BestBETS2010

115. When Clopidogrel Fails…

When Clopidogrel Fails… When Clopidogrel Fails… | Clinical Correlations When Clopidogrel Fails… March 10, 2010 Marisa Mizus Faculty peer reviewed Clopidogrel ( Plavix ) has been the standard of care for patients with coronary artery disease following percutaneous coronary intervention (PCI) for the past decade. Although it is a successful antiplatelet treatment in many patients, like any hero, it has a weakness: formation of its active metabolite depends on two hepatic cytochrome P450 (CYP450 (...) )-dependent steps. Clopidogrel resistance, or non-response, is correlated with an increased risk of major adverse cardiovascular events, including reinfarction and stent thrombosis.(1) It is often unclear why a patient does not respond to clopidogrel, although there is speculation that clopidogrel resistance results from the attenuating effects of proton pump inhibitors (PPIs) and CYP450 reduced function polymorphisms.(2) Patients showing inadequate platelet response to clopidogrel have been treated

Clinical Correlations2010

116. Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention. Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38

Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention. Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 20026770 2010 01 05 2010 01 28 2015 11 19 1524-4539 121 1 2010 Jan 05 Circulation Circulation Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial (...) to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. 71-9 10.1161/CIRCULATIONAHA.109.900704 In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel

EvidenceUpdates2010

117. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasug

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasug Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition (...) With Prasugrel - Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel - Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ Record Status This is a critical

NHS Economic Evaluation Database.2010

118. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K CRD summary This review concluded that concomitant use (...) of proton pump inhibitors and clopidogrel might be associated with an increased risk of cardiovascular events but did not influence the risk of death in patients with established cardiovascular disease. These cautious conclusions appear appropriate, although risk of publication bias and lack of details on study quality should be borne in mind. Authors' objectives To assess whether proton pump inhibitors negatively affect clinical outcomes in patients treated with clopidogrel. Searching MEDLINE, EMBASE, Cochrane Central

DARE.2010

119. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis

New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, Barthelemy O, Collet JP, Montalescot G CRD summary The review concluded that new P2Y 12 inhibitors decreased all-cause mortality and major (...) ischaemic events after percutaneous coronary intervention compared with clopidogrel, but increased major and minor bleeding. Bleeding was not significantly increased for ST-segment elevation myocardial infarction patients. Uncertain study quality and grouping of different P2Y 12 inhibitors together made the reliability of the authors’ conclusions unclear. Authors' objectives To compare the efficacy and safety of new P2Y 12 inhibitors versus clopidogrel after percutaneous coronary intervention. Searching

DARE.2010

120. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK

A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK Karnon J, Holmes MW, Williams R, Bakhai A, Brennan A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study aimed to assess the incremental cost-effectiveness of treatment for one month or for one year, with clopidogrel in addition to standard therapy, for patients diagnosed with ST-segment elevation myocardial infarction, in the UK. The authors concluded that the addition of clopidogrel to standard therapy was cost

NHS Economic Evaluation Database.2010